tbuckley/cabot-search huggingface dataset:
Abstract LB-304: Evaluation of the effects of anti-VEGF therapy in a multidisciplinary phase I/II study of neoadjuvant bevacizumab with chemoradiation therapy in rectal cancer
Authors: Christopher G Willett, Lei Xu, Dan G Duda, Emmanuelle di Tomaso, Yves Boucher, Johanna Lahdenranta, Marek Ancukiewicz, Johanna Bendell, Brian Czito, Lawrence Blaszkowsky, Jeffrey Clark, Rakesh K Jain
Journal: Cancer Research (2008)

Abstract Background: A phase I/II study of neoadjuvant bevacizumab with 5-fluorouracil and radiation therapy in patients with locally advanced rectal cancer is underway to assess the clinical benefits of bevacizumab enhancement of chemo-radiation therapy. Methods: 24 patients with endoscopic ultrasound or surface coil MRI staged T3/T4 non-metastatic rectal cancer were enrolled from 2001-2007. All patients completed 4 cycles of neoadjuvant therapy including: 1) bevacizumab infusion (5 or 10 mg/kg) on day 1 of each cycle; 2) peripheral venous infusion 5-FU (225 mg/m2/24 hours) administration each treatment week of cycles 2 - 4; 3) external beam irradiation delivery (50.4 Gy in 28 fractions over 5.5 weeks); and 4) surgery 7 to 9 weeks after completion of all neoadjuvant therapy. Correlative studies are undertaken before and during the trial. We collected serial tumor biopsies, PET-FDG scans, and analyzed blood and urine for potential biomarkers. Results: Histologic examination showed no residual primary cancer in 5 patients (ypT0). Of 19 patients with residual disease, microscopic disease usually occurred as malignant glands embedded in fibrosis (ypT1 in 3 patients, ypT2 in 4 patients, ypT3-4 in 12 patients). Downstaging was seen in 12/22 tumors. Nine patients had microscopic nodal metastases. Bevacizumab alone and combined treatment were both associated with increased plasma VEGF, PlGF and SDF1alpha levels in analyzed patients (P&amp;lt;0.01 at all 4 timepoints compared to baseline). Viable CECs were decreased by VEGF blockade at day 3 (P&amp;lt;0.01 compared to baseline), and CEC levels correlated with histologic tumor response (T3 vs T0, p &amp;lt;0.05). Laser-capture micro-dissection identified a set of genes changed by anti-VEGF therapy in cancer cells as well as in tumor-associated macrophages. Actuarial 4 year local control and disease-free are 100% and 88%, respectively. Conclusions: Addition of bevacizumab at a dose of 5 mg/kg to standard chemo-radiation shows activity and the combined regimen yields promising results.
Otoneurological examination in panic disorder and agoraphobia with panic attacks: a pilot study
Authors: R G Jacob, M B Møller, S M Turner, C Wall
Journal: American Journal of Psychiatry (1985)

A battery of vestibular and audiological tests was administered to eight patients with panic disorder and 13 patients with agoraphobia and panic attacks, all of whom experienced dizziness during their panic attacks. Positional or spontaneous nystagmus was present in 67% of the subjects. Abnormal responses were found in caloric testing (56%), rotational testing (35%), and posturography (32%). Pure tone audiograms were abnormal in 26% of the subjects and acoustic reflexes were abnormal in 44% of the subjects. Six of eight patients tested had an abnormal brainstem auditory evoked potential. The possible importance of the findings and their implications for further research are discussed.
Comparison of different measures of blood pressure
Authors: W. T Hamilton
Journal: BMJ (2002)

Concerns of clinicians and patients need to be addressed firstEditor-Chantler and Johnson suggested that patients should receive copies of letters and summaries. 1We have researched this subject in our practice since 1998. 2 Our experience of copying referral letters received such a positive response from patients that we have been doing this routinely for the past year and a half.In a recent postal survey of 300 patients who had received copies of letters, 229 replied (response rate 76%), 220 (97%) of them saying that they would like to receive copies in future.Most of the respondents (184, 80%) believed that this should become routine NHS policy and should receive priority funding.Few concerns were raised about understanding the letters, and patients did not report increased anxiety; rather, they were reassured that their problem was being dealt with and they could understand why they were being referred.Copying letters has not notably increased workload for doctors in our practice in terms of extra consulting time with patients, but financial costs are incurred in additional administrative time, stationery, and postage.We therefore broadly agree with Chantler and Johnson's argument that this is a policy that, if adequately funded, should be implemented forthwith.We have, however, also just completed a series of interviews with a random sample of local general practitioners, all of whom raised some important concerns.They worry about how to write letters that are both comprehensible for patients and informative for professional colleagues, and how to avoid anxiety in patients when writing about tentative but potentially serious differential diagnoses.
Does Liver Therapy Benefit the Diabetic?
Authors: Elmer L. Sevringhaus
Journal: Annals of Internal Medicine (1932)

Article1 May 1932Does Liver Therapy Benefit the Diabetic?ELMER L. SEVRINGHAUS, M.D., F.A.C.P.ELMER L. SEVRINGHAUS, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-5-11-1387 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAs a consequence of the reports of Blotner and Murphy1a number of trials have been made in this hospital with liver therapy for diabetes mellitus. The first of these was made with feeding of whole liver, 180 grams daily, to two cases of clinically unvarying tolerance. The results gave no encouragement at that time (1929). In July, 1930, our attention was directed to the possible merits of a mixture of an extract of horse liver, horse blood, with hypophosphites, alcohol, and saccharin, referred to below as "liver mixture". The manufacturers of a certain commercial horse liver and blood mixture...References1 BLOTNERMURPHY HWP: Effect of certain liver extracts on the blood sugar of diabetic patients, Jr. Am. Med. Assoc., 1930, xciv, 1811-1816. CrossrefGoogle Scholar2 STEPHAN R: Über die Wirkungsart des gallensauren Insulins bei subkutaner Anwendungsform, Deutsch. med. Wchnschr., 1930, lvi, 88-97. CrossrefGoogle Scholar3 DE PENCIERSOSKINBEST MTSCH: Effect of liver on blood sugar level and on sugar excretion of depancreatized dogs, Am. Jr. Physiol., 1930, xciv, 548-552. CrossrefGoogle Scholar4 SOSKINBINSWANGERSTROUSE SHFS: Jerusalem artichokes and liver in the treatment of diabetes mellitus, Jr. Clin. Invest., 1931, x, 169. Google Scholar5 ROOT HF: Diabetes and pernicious anemia, Jr. Am. Med. Assoc., 1931, xcvi, 928-933. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: ELMER L. SEVRINGHAUS, M.D., F.A.C.P.Affiliations: Madison, Wisconsin*From the Department of Medicine and the Wisconsin General Hospital, University of Wisconsin, Madison, Wisconsin.†Received for publication, August 10, 1931. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1932Volume 5, Issue 11 Page: 1387-1390 Keywords Alcohols Blood Diabetes mellitus Hospital medicine Liver ePublished: 1 December 2008 Issue Published: 1 May 1932 PDF downloadLoading ...
Revisiting an ancient treatment for transphincteric fistula-in-ano ‘There is nothing new under the sun’ Ecclesiastes 1v9
Authors: F Soliman, G Sturgeon, R Hargest
Journal: Journal of the Royal Society of Medicine (2015)

Objective The history of treatments for fistula-in-ano can be traced back to ancient times. Current treatment of transphincteric fistulae is controversial, with many options available. We reviewed the history of treatment using cutting setons and present our series of transphincteric fistulae in the light of the series in the literature. Design Literature review and case series. Setting Hospital based coloproctology service Participants 140 consecutive patients presenting with fistula-in-ano were included. Main Outcome Measures The literature pertaining to treatment of transphincteric fistula was reviewed, along with the outcome of various treatment methods for this condition. Data were collected for 140 consecutive patients presenting with fistula- in-ano were assessed for fistula healing, recurrence and complications. Results A total of 140 consecutive patients with fistula-in-ano were identified, of which 111 were cryptoglandular (79.3%). Eighty-one of these 111 were transphincteric (73.0%). At a median follow-up of 35 months (range, 2–83 months), 70 transphincteric fistulae had healed (86.4%), 10 were still undergoing treatment (12.3%) and one patient was lost to follow-up prior to treatment (1.2%). Two patients in this group required a stoma (2.5%), six patients developed recurrence (7.4%); three ‘true’ recurrences (3.7%). One (1.2%) developed a chronic fissure. There were no reported cases of incontinence. Conclusions The management of transphincteric fistula-in-ano is complex and controversial, for which no clear surgical procedure has gained acceptance as the gold standard. This study demonstrates that transphincteric fistulae can be successfully treated using cutting setons. A high healing rate (86.4%), low recurrence rate (7.4%) and a low complication rate (3.7%) are shown, which compares favourably with published rates over a long follow-up.
Abstract 77: Nitric Oxide in Sepsis: Friend or Foe? Hemodynamics in a Murine Model
Authors: Steven Hollenberg, Massimiliano Guglielmi, Sergio Zanotti, Jad Skaf, Tracy Walker, Magali Zanotti, Joseph E Parrillo
Journal: Circulation (2006)

Introduction: Overproduction of NO by inducible nitric oxide synthase (iNOS) in sepsis has been implicated in vascular relaxation associated with hypotension and in myocardial depression, but wheth...
Abstract 4517: High Dose Allopurinol is Anti-Ischaemic in Chronic Stable Angina
Authors: Awsan Noman, Donald S Ang, Simon Ogston, Chim C Lang, Allan D Struthers
Journal: Circulation (2009)

Background:  Experimental evidence suggests that xanthine oxidase inhibitors (XOIs) can somehow reduce myocardial oxygen consumption for a given stroke volume. If such an effect also occurred in man, the possibility arises that XOIs could become a new anti-ischaemic agent in angina pectoris.   Aim:  To investigate if allopurinol has anti-ischaemic effects in chronic stable angina   Methods:  Sixty-five patients with stable chronic angina pectoris were recruited for a double blind, randomised, placebo controlled crossover study. They were randomised to receive either allopurinol (600 mg/day) or placebo for 6 weeks and then crossed over. Prior to randomisation and at the end of each treatment period, patients underwent an exercise tolerance test.   Results:  Allopurinol significantly increased total exercise time, time to ST depression and time to symptoms compared to placebo (see table 1). In addition, the systolic blood pressure at the end of the first stage of the Bruce protocol was significantly lower in the allopurinol arm (−6.1 mmHg) compared to placebo (−1.6 mmHg) (p=0.026). A higher heart rate and rate pressure product was achieved at peak exercise in the allopurinol arm compared to placebo.   Conclusion:  In stable angina pectoris, high dose allopurinol has anti-ischaemic properties. Further research is needed to define the best place for high dose allopurinol in the overall management of angina pectoris.
Tolerance and efficacy of intravesical BCG treatment in non muscle-invasive bladder carcinoma after renal transplantation.
Authors: Avinash Jayaswal, Thierry Roumeguere, Emine Nilufer Broeders, Thierry Quackels, Sandrine Rorive, Anne Lemy, Joëlle Nortier
Journal: Journal of the American Society of Nephrology (2011)
Abstract 3064: Assessment of Coronary Intervention by Optical Coherence Tomography in Acute Coronary Syndrome: Comparison with Stable and Unstable Angina
Authors: Takashi Kubo, Takashi Masyo, Takashi Yamano, Shigeho Takarada, Toshio Imanishi, Yoshiaki Tomobuchi, Takashi Akasaka
Journal: Circulation (2006)
The Relationship of Operability and Hemoglobin Percentage in Carcinoma of the Stomach
Authors: Howard R. Hartman, Thomas William Brockbank
Journal: Annals of Internal Medicine (1928)

Article1 December 1928The Relationship of Operability and Hemoglobin Percentage in Carcinoma of the StomachHOWARD R. HARTMAN, M.D., THOMAS WILLIAM BROCKBANK, M.D.HOWARD R. HARTMAN, M.D.Search for more papers by this author, THOMAS WILLIAM BROCKBANK, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-2-6-503 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt is commonly known that anemia may accompany carcinoma in any region of the body, particularly if the malignancy is advanced or if the vital abdominal organs are involved. In malignancy of the gastro-intestinal tract, anemia is probably most severe if carcinoma involves the stomach (1), but the changes in the blood in similar lesions in the proximal colon (1, 3) call for further investigation. That anemia, in the presence of carcinoma of the stomach, bears some relationship to the operability of the lesion is often implied by the internist as well as the surgeon. We have been unable to...Bibliography(1) EISEN D: The anemia of cancer of the gastro-intestinal tract based on study of 187 cases. Can. Med. Assn. Jour., 1927, xvii, 307-313. Google Scholar(2) OSLERMCCRAE WT: Cancer of the stomach; a clinical study. Philadelphia, P. Blakeston's Sons and Company. 1900, 157 pp. Google Scholar(3) PRICKMAN LE: The changes in the blood picture with carcinoma of the colon. Proc. of the Staff Meetings of The Mayo Clinic, 1927, ii, 80-82. Google Scholar(4) SMITHIES F: Cancer of the stomach; a clinical study of 921 operatively and pathologically demonstrated cases. Philadelphia. W. B. Saunders Company. 1916, 522 pp. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Submitted for publication July 16, 1928. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1928Volume 2, Issue 6Page: 503-508KeywordsAnemiaBloodColonGastroenterology and hepatologyHemoglobinLesionsStomachSurgeons ePublished: 1 December 2008 Issue Published: 1 December 1928 PDF downloadLoading ...
PSYCHOLOGICAL CONSIDERATIONS IN THE TREATMENT OF THE NEUROSES
Authors: Arthur H. Jackson
Journal: Annals of Internal Medicine (1934)

Article1 August 1934PSYCHOLOGICAL CONSIDERATIONS IN THE TREATMENT OF THE NEUROSESARTHUR H. JACKSON, M.D.ARTHUR H. JACKSON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-8-2-214 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThere can be little question but that a very large proportion of those who consult their physicians for other than purely surgical, acute infectious or obstetrical conditions are suffering from some form of neurosis, which, in many cases, is psychogenic in origin. Thefunctionof some organ or organs is at fault while the organ itself is in no way diseased. The diagnosis of such a condition as some form of organic disease is one of the commonest errors in diagnosis met with today. The battle-scarred abdominal wall of one who has submitted to one surgical procedure after another in... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Washington, Connecticut*Received for publication March 20, 1934.From the Department of Internal Medicine, Yale University School of Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1934Volume 8, Issue 2Page: 214-219 ePublished: 1 December 2008 Issue Published: 1 August 1934 PDF downloadLoading ...
Quantification of Myocardial Blood Flow in Absolute Terms Using 82Rb PET Imaging
Authors: Sergey V. Nesterov, Emmanuel Deshayes, Roberto Sciagrà, Leonardo Settimo, Jerome M. Declerck, Xiao-Bo Pan, Keiichiro Yoshinaga, Chietsugu Katoh, Piotr J. Slomka, Guido Germano, Chunlei Han, Ville Aalto, Adam M. Alessio, Edward P. Ficaro, Benjamin C. Lee, Stephan G. Nekolla, Kilem L. Gwet, Robert A. deKemp, Ran Klein, John Dickson, James A. Case, Timothy Bateman, John O. Prior, Juhani M. Knuuti
Journal: JACC. Cardiovascular imaging (2014)
Abstract 2011: A Simple Nomogram to Predict the Probability of Successful Reperfusion with Pre-Hospital Thrombolysis
Authors: Vanina Bongard, Jacques Puel, Dominique Savary, Sandrine Charpentier, Loic Belle, Christophe Loubeyre, Darko Miljkovic, Boehringer Ingelheim, Yves Cottin, Philippe G Steg, Meyer Elbaz
Journal: Circulation (2008)

In ST-elevation myocardial infarction (STEMI), coronary recanalisation is a prerequisite for deriving benefit from thrombolysis, but achieving myocardial reperfusion is also key to benefit. Data regarding the impact of thrombolysis on myocardial reperfusion are scarcer than for recanalisation, especially when pre-hospital thrombolysis is considered. To develop a nomogram for predicting myocardial reperfusion after pre-hospital thrombolysis. In 2004 – 05, 800 consecutive French patients with STEMI received pre-hospital thrombolysis within 6 hours of symptom onset (median delay of 110 minutes). The assessment of myocardial reperfusion was based on the measurement of ST resolution (STR) between a first electrocardiogram (ECG), recorded before thrombolysis, and a second one in the cath laboratory. Myocardial reperfusion was assessed when STR was 70%, at least, in the single lead with the greatest baseline ST-elevation. The sample comprised 18% of women and median age was 59. The median delay between the two ECGs was 110 minutes. The proportion of patients who achieved STR was 42%. The nomogram was based on the variables that were independently associated with STR in multivariate logistic regression analysis. For instance, a non-obese smoker patient, with a non-anterior STEMI and a maximum ST-elevation of 2 mm, for whom thrombolysis is possible within 1 hour of symptom onset, together with the administration of a thienopyridine, but no IV nitrates, has a probability of 0.87 to achieve STR. If thrombolysis is delayed after one hour, without thienopyridine administration, in case of anterior STEMI, the probability declines to 0.50. The probabilities of STR for the different situations covered by the nomogram range from 0.10 to 0.87. This nomogram, developed in a “real world” setting, is designed to predict a priori the probability of myocardial reperfusion following thrombolysis, based on simple clinical and electrocardiographic data.
Editors and Owners of Scientific Journals
Authors: Jack T. Evjy
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide (EC or HEC) with cyclophosphamide, methotrexate, and fluorouracil (CMF) in 777 women with node-positive (N+) breast cancer (BC): 10-year follow-up results
Authors: E. Azambuja, M. Paesmans, C. Bernard-Marty, M. Beauduin, A. Vindevoghel, N. Cornez, C. Focan, A. Tagnon, J. M. Nogaret, M. Piccart-Gebhart
Journal: Journal of Clinical Oncology (2006)

568 Background: The purpose of this presentation is to provide an update, with longer follow up data, of the results of this Belgian multicentric trial, which had shown a dose response curve for epirubicin at a median follow up of 4 years (Piccart et al, J Clin Oncol 2001; 19:3103–3110) Methods: In this prospective, open label, randomized trial of the 1990’s, patients aged from 18 to 70 years were stratified by center, 1–3 vs 4 or more nodes, and menopausal status (pre- vs postmenopausal). The primary hypothesis was that HEC could be associated with an increase in event-free survival (EFS) compared with CMF. Patients received CMF (oral cyclophosphamide days 1–14) for six cycles, EC (epirubicin 60 mg/m 2 , cyclophosphamide 500 mg/m 2 day 1 every 3 weeks) for eight cycles or HEC (epirubicin 100 mg/m 2 , cyclophosphamide 830 mg/m 2 day 1 every 3 weeks) for eight cycles. Tamoxifen followed chemotherapy in postmenopausal women with positive or unknown hormone receptor (HR). Two hundred fifty-five, 267, and 255 eligible patients were treated with CMF, EC, and HEC, respectively. Results: The trial results are now updated, with an actuarial median follow-up of 12.2 years. Using Kaplan-Meier estimation, the 10-year EFS is 55% for patients who received CMF, 48% for EC patients, and 58% for HEC patients. The hazard ratios obtained from Cox regression models (HR) are, for EC vs HEC, 1.30 (95% confidence interval [CI], 1.02 to 1.67, P = .03); for CMF vs HEC, 1.12 (95% CI, 0.87 to 1.44, P = .39); and for CMF vs EC, 1.17 (95% CI, 0.92 to 1.48, P = .21). Kaplan-Meier estimates of the 10-year overall survival rates are 65% for patients who received CMF, 65% for EC patients, and 70% for HEC patients, with no significant differences among the three arms. Conclusions: The short term results of this trial are nicely confirmed at 10 years: in patients unselected for HR or HER-2 status, the dose intensity of epirubicin matters. Analysis in subsets of patients is ongoing, but will be only hypothesis-generating. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, sanofi-aventis, Bristol-Myers Squibb, GlaxoSmithKline, Johnson &amp; Johnson, Novartis, Pfizer, Schering-Plough Amgen, AstraZeneca, Eli Lilly, Novartis, Pfizer, Roche, sanofi-aventis, Schering-Plough
IL-6 Promotes Cell Proliferation and Antiapoptosis Through Activation Of The JAK/STAT3 Pathway In Patients With NK/T - Cell Lymphoma and Correlates With Poor Treatmemt Outcome
Authors: Qichun Cai, Hui-qiang Huang, Bing Bai, Suxia Lin, Yan Gao, Yi Xia, XiaoXiao Wang, Jiabin Lu
Journal: Blood (2013)
Abstract 16748: Predictors of Bioprosthetic Aortic Valve Failure: Results in 73,616 Patients from the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery National Database
Authors: J. Matthew Brennan, Eric D Peterson, Yue Zhao, Sean O'Brien, Rachel Dokholyan, Pamela S Douglas, Fred H Edwards
Journal: Circulation (2010)

Background: Bioprostheses are increasingly used for aortic valve replacement (AVR); however, their durability remains a concern. We sought to identify factors associated with early reoperation in c...